-
Mashup Score: 8GERMLINE PATHOGENIC VARIANTS IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA AND EXTRA-PANCREATIC MALIGNANCIES: A NATIONWIDE DATABASE ANALYSIS - 10 day(s) ago
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease. About 10% of affected individuals have an inherited component. Deleterious germline variants increase the lifetime risk for PDAC and are often associated with an elevated risk for extra-pancreatic malignancies. In this study, we aim to determine the prevalence and impact of germline pathogenic variants (gPVs) in patients with PDAC and extra-pancreatic malignancies. Using tissue samples and longitudinal data from a nationwide pathology database, we identified patients with PDAC and a set of seven extra-pancreatic malignancies to investigate the presence of gPVs in 25 cancer susceptibility genes with targeted next-generation sequencing.
Source: www.modernpathology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 423
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Over the previous 2 decades, tremendous progress has been made in our understanding of the molecular pathogenesis of DLBCL. However, this biological understanding has not yet been translated into improved first-line therapy. A major barrier to the introduction of molecularly targeted therapy in DLBCL is the considerable molecular heterogeneity of this disease. Recent studies have tried to rationalize this heterogeneity by proposing new genetic subtypes of DLBCL.
Source: www.modernpathology.orgCategories: General Medicine News, Hem/OncsTweet-
Molecular classification of DLBCL Solid table for lymphoma geeks such as myself https://t.co/wObti6L9m1 https://t.co/VbplXmo64q
-
-
Mashup Score: 409
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Over the previous 2 decades, tremendous progress has been made in our understanding of the molecular pathogenesis of DLBCL. However, this biological understanding has not yet been translated into improved first-line therapy. A major barrier to the introduction of molecularly targeted therapy in DLBCL is the considerable molecular heterogeneity of this disease. Recent studies have tried to rationalize this heterogeneity by proposing new genetic subtypes of DLBCL.
Source: www.modernpathology.orgCategories: General Medicine News, Hem/OncsTweet-
Molecular classification of DLBCL Solid table for lymphoma geeks such as myself https://t.co/wObti6L9m1 https://t.co/VbplXmo64q
-
-
Mashup Score: 409
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Over the previous 2 decades, tremendous progress has been made in our understanding of the molecular pathogenesis of DLBCL. However, this biological understanding has not yet been translated into improved first-line therapy. A major barrier to the introduction of molecularly targeted therapy in DLBCL is the considerable molecular heterogeneity of this disease. Recent studies have tried to rationalize this heterogeneity by proposing new genetic subtypes of DLBCL.
Source: www.modernpathology.orgCategories: General Medicine News, Hem/OncsTweet-
Molecular classification of DLBCL Solid table for lymphoma geeks such as myself https://t.co/wObti6L9m1 https://t.co/VbplXmo64q
-
-
Mashup Score: 409
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Over the previous 2 decades, tremendous progress has been made in our understanding of the molecular pathogenesis of DLBCL. However, this biological understanding has not yet been translated into improved first-line therapy. A major barrier to the introduction of molecularly targeted therapy in DLBCL is the considerable molecular heterogeneity of this disease. Recent studies have tried to rationalize this heterogeneity by proposing new genetic subtypes of DLBCL.
Source: www.modernpathology.orgCategories: General Medicine News, Hem/OncsTweet-
Molecular classification of DLBCL Solid table for lymphoma geeks such as myself https://t.co/wObti6L9m1 https://t.co/VbplXmo64q
-
-
Mashup Score: 54Acute promyelocytic leukemia with torque teno mini virus (TTMV)::RARA fusion: an approach to screening and diagnosis - 9 month(s) ago
Acute promyelocytic leukemia (APL) with variant RARA translocation is linked to over 15 partner genes. Recent publications encompassing six cases have expanded the spectrum of RARA partners to torque teno mini virus (TTMV). This entity is likely under-recognized due to lack of clinician and pathologist familiarity, inability to detect the fusion using routine testing modalities, and informatic challenges in its recognition within next-generation sequencing (NGS) data. We describe a clinicopathologic approach and provide necessary tools to screen and diagnose APL with TTMV::RARA using existing clinical DNA or RNA-based NGS assays, which led to identification of four cases, all without other known cytogenetic/molecular drivers.
Source: www.modernpathology.orgCategories: General Medicine News, Hem/OncsTweet-
Have you ever had a case you were very suspicious was acute promyelocytic leukemia, but all RARA testing was negative? It could be APML with torque teno mini virus (TTMV)::RARA fusion. #hemepath #pathtwitter #hemeonc #hematology https://t.co/haGN3wIF7h
-
-
Mashup Score: 925th Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissues: B-cell Neoplasms - 12 month(s) ago
We review B-cell lymphomas in the 5th edition of the World Health Organization classification of hematolymphoid tumors (WHO-HEM5). The revised classification is based on a multidisciplinary approach including input from pathologists, clinicians and other experts. The WHO-HEM5 follows a hierarchical structure allowing use of family (class)-level definitions when defining diagnostic criteria are partially met or a complete investigational workup is not possible. Disease types and subtypes have expanded compared with the WHO revised 4th edition (WHO-HEM4R), mainly because of the expansion in genomic knowledge of these diseases.
Source: www.modernpathology.orgCategories: General Medicine News, Hem/OncsTweet-
Out today 🚨all you need to know about B cell lymphoma Dx in one beautiful paper @ljmedeirosMD @YasoNatkunam #hemepath @ModernPathology #lymsm https://t.co/5o5dLoAUvZ
-
-
Mashup Score: 1565TH EDITION OF THE WORLD HEALTH CLASSIFICATION OF TUMORS OF THE HEMATOPOIETIC AND LYMPHOID TISSUES - 12 month(s) ago
In this manuscript, we review myeloid neoplasms in the 5th edition of the World Health Organization classification of hematolymphoid tumors (WHO-HEM5), focusing on changes from the revised 4th edition (WHO-HEM4R). Disease types and subtypes have expanded compared with WHO-HEM4R, mainly because of the expansion in genomic knowledge of these diseases. The revised classification follows a hierarchical structure allowing usage of family (class) level definitions where the defining diagnostic criteria are partially met or a complete investigational workup has not been possible.
Source: www.modernpathology.orgCategories: General Medicine News, Hem/OncsTweet-
Out 2day @ModernPathology how we apply #WHO in the Dx of myeloid neoplasms in practice Huge🙏🏻@MrinalPatnaik @JoeKhouryMD @kanagalshamanna @ljmedeirosMD Drs Nejati & Kikeri 4 invaluable contributions 2 this 📄 ✅ out the case examples, they R 👌🏻 https://t.co/Ylcru6DO1r #hemepath https://t.co/KTCgKFjUia
-
-
Mashup Score: 1335TH EDITION OF THE WORLD HEALTH CLASSIFICATION OF TUMORS OF THE HEMATOPOIETIC AND LYMPHOID TISSUES - 1 year(s) ago
In this manuscript, we review myeloid neoplasms in the 5th edition of the World Health Organization classification of hematolymphoid tumors (WHO-HEM5), focusing on changes from the revised 4th edition (WHO-HEM4R). Disease types and subtypes have expanded compared with WHO-HEM4R, mainly because of the expansion in genomic knowledge of these diseases. The revised classification follows a hierarchical structure allowing usage of family (class) level definitions where the defining diagnostic criteria are partially met or a complete investigational workup has not been possible.
Source: www.modernpathology.orgCategories: General Medicine News, Hem/OncsTweet-
Out 2day @ModernPathology how we apply #WHO in the Dx of myeloid neoplasms in practice Huge🙏🏻@MrinalPatnaik @JoeKhouryMD @kanagalshamanna @ljmedeirosMD Drs Nejati & Kikeri 4 invaluable contributions 2 this 📄 ✅ out the case examples, they R 👌🏻 https://t.co/Ylcru6DO1r #hemepath https://t.co/KTCgKFjUia
-
-
Mashup Score: 1305TH EDITION OF THE WORLD HEALTH CLASSIFICATION OF TUMORS OF THE HEMATOPOIETIC AND LYMPHOID TISSUES - 1 year(s) ago
In this manuscript, we review myeloid neoplasms in the 5th edition of the World Health Organization classification of hematolymphoid tumors (WHO-HEM5), focusing on changes from the revised 4th edition (WHO-HEM4R). Disease types and subtypes have expanded compared with WHO-HEM4R, mainly because of the expansion in genomic knowledge of these diseases. The revised classification follows a hierarchical structure allowing usage of family (class) level definitions where the defining diagnostic criteria are partially met or a complete investigational workup has not been possible.
Source: www.modernpathology.orgCategories: General Medicine News, Hem/OncsTweet-
Out 2day @ModernPathology how we apply #WHO in the Dx of myeloid neoplasms in practice Huge🙏🏻@MrinalPatnaik @JoeKhouryMD @kanagalshamanna @ljmedeirosMD Drs Nejati & Kikeri 4 invaluable contributions 2 this 📄 ✅ out the case examples, they R 👌🏻 https://t.co/Ylcru6DO1r #hemepath https://t.co/KTCgKFjUia
-
Link to paper below: GERMLINE PATHOGENIC VARIANTS IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA AND EXTRA-PANCREATIC MALIGNANCIES: A NATIONWIDE DATABASE ANALYSIS https://t.co/2dEeydyakv